BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ali AS, Langer SW, Federspiel B, Hjortland GO, Grønbæk H, Ladekarl M, Welin S, Weber Vestermark L, Arola J, Osterlund P, Knigge U, Sørbye H, Micke P, Grimelius L, Grönberg M, Tiensuu Janson E. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS One 2020;15:e0243900. [PMID: 33315908 DOI: 10.1371/journal.pone.0243900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Bai R, Li W, Cui J. Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. Cancer Biol Med 2022;19:1649-61. [PMID: 36245210 DOI: 10.20892/j.issn.2095-3941.2022.0489] [Reference Citation Analysis]
2 Rösner E, Kaemmerer D, Sänger J, Lupp A. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. Transl Oncol 2022;25:101526. [PMID: 36067541 DOI: 10.1016/j.tranon.2022.101526] [Reference Citation Analysis]
3 Smolkova B, Kataki A, Earl J, Ruz-caracuel I, Cihova M, Urbanova M, Buocikova V, Tamargo S, Rovite V, Niedra H, Schrader J, Kohl Y. Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103865] [Reference Citation Analysis]
4 Raderer M, Kiesewetter B. The NET G3 enigma: dealing with a “new” entity. memo 2022. [DOI: 10.1007/s12254-022-00848-z] [Reference Citation Analysis]
5 Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World J Gastroenterol 2021; 27(47): 8123-8137 [DOI: 10.3748/wjg.v27.i47.8123] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Centonze G, Lagano V, Sabella G, Mangogna A, Garzone G, Filugelli M, Belmonte B, Cattaneo L, Crisafulli V, Pellegrinelli A, Simbolo M, Scarpa A, Spaggiari P, Brambilla T, Pusceddu S, Prinzi N, Anichini A, Tripodo C, Milione M. Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. J Clin Med 2021;10:1741. [PMID: 33920514 DOI: 10.3390/jcm10081741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, Sciallero S, Boschetti M, Ferone D. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 2021;22:615-36. [PMID: 33851319 DOI: 10.1007/s11154-021-09647-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Koumarianou A, Kaltsas GA, Chatzellis E, Kyriakopoulos G, Kolomodi D, Alexandraki KI. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine 2021;73:232-9. [PMID: 33544352 DOI: 10.1007/s12020-021-02639-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]